Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Companyâs therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Companyâs portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimerâs disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimerâs disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
æé·äž
åç€Ÿã¯æé·ãã§ãŒãºã«ãããææ°ã®å¹Žéåçã¯USD 72.10Kã«éããŠããŸãã
å²å®
åç€Ÿã®ææ°ã®PEã¯-15.66ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠå®å€åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯1.31Mæ ªã§ãåååææ¯ã§32.90%æžå°ããŠããŸãã
åžå ޿޻åãäœèª¿
å瀟ãžã®æè³å®¶ã®é¢å¿ã¯äœäžããŠããã20æ¥éã®å£²è²·å転çã¯-0.97ã§ãã